Calendario›TCRT›Ad-RTS-hIL-12

Ad-RTS-hIL-12

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

Ensayo de Alaunos Therapeutics, Inc. en Glioblastoma.

Más ensayos de: Glioblastoma.

Fase

Fase 1

Estado

Completado

Participantes

21

previstos

Centros

4

Fin del objetivo primario

oct 2020

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en jun 2018.

Qué mide

Number of Participants With Adverse Events (AEs) (2 years and 4 months) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human interleukin-12 (IL-12). IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Nivolumab is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Opdivo (Nivolumab) is currently FDA approved in the United States for melanoma (a type of skin cancer), non-small cell lung cancer, renal cell cancer (a type of kidney cancer), Hodgkin's lymphoma but is not approved in glioblastoma. Nivolumab may help your immune system detect and attack cancer cells. Ad-RTS-hIL-12 and veledimex will be given in combination with Nivolumab to enhance the IL-12 mediated effect observed to date. The main purpose of this substudy is to evaluate the safety and tolerability of a single tumoral injection of Ad-RTS-hIL-12 given with oral veledimex in combination with nivolumab.

Más ensayos de TCRT

Todos los de TCRT, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03636477), actualizada en ago 2025.